1
|
Gutierrez C, Peirone M, Carranza A, Di Girolamo G, Bonazzola P, Castilla R. Mild hyperbaric oxygen exposure protects heart during ischemia/reperfusion and affects vascular relaxation. Pflugers Arch 2024:10.1007/s00424-024-02992-3. [PMID: 39052036 DOI: 10.1007/s00424-024-02992-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2024] [Revised: 07/05/2024] [Accepted: 07/16/2024] [Indexed: 07/27/2024]
Abstract
Mild hyperbaric oxygen therapy (mHBOT) is an adjuvant therapy used in conditions where tissue oxygenation is reduced and is implemented using pressures less than 1.5 ATA and 100% O2 (instead of the classical HBOT at 1.9-3 ATA) which results in cheaper, easier to implement, and equally effective. mHBOT is offered for wellness and beauty and as an anti-aging strategy, in spite of the absence of studies on the cardiovascular system. Consequently, we investigated the impact of mHBOT on the cardiovascular system. Mechanical and energetic parameters of isolated heart submitted to ischemia/reperfusion injury and arterial contractile response from mHBOT-exposed rats were evaluated. In the heart, mHBOT increased pre-ischemic velocity of contraction and ischemic end-diastolic pressure and developed pressure and contractile economy during reperfusion. mHBOT decreased infarct size and increased the plasma nitrite levels. In the artery, mHBOT increased acetylcholine sensitivity. mHBOT protects the heart during ischemia/reperfusion and affects vascular relaxation.
Collapse
Affiliation(s)
- Christopher Gutierrez
- Instituto Alberto C Taquini de Investigaciones en Medicina Traslacional (IATIMET), CONICET, Universidad de Buenos Aires, Marcelo T. de Alvear 2270, Ciudad Autónoma de Buenos Aires, C1122AAJ, Argentina
| | - Magdalena Peirone
- Instituto Alberto C Taquini de Investigaciones en Medicina Traslacional (IATIMET), CONICET, Universidad de Buenos Aires, Marcelo T. de Alvear 2270, Ciudad Autónoma de Buenos Aires, C1122AAJ, Argentina
| | - Andrea Carranza
- Cátedra de Farmacología, Departamento de Farmacología, Facultad de Farmacia y Bioquímica, CONICET, Universidad de Buenos Aires, Junín 956, C1113AAD, Ciudad Autónoma de Buenos Aires, Argentina
| | - Guillermo Di Girolamo
- Instituto Alberto C Taquini de Investigaciones en Medicina Traslacional (IATIMET), CONICET, Universidad de Buenos Aires, Marcelo T. de Alvear 2270, Ciudad Autónoma de Buenos Aires, C1122AAJ, Argentina
| | - Patricia Bonazzola
- Instituto Alberto C Taquini de Investigaciones en Medicina Traslacional (IATIMET), CONICET, Universidad de Buenos Aires, Marcelo T. de Alvear 2270, Ciudad Autónoma de Buenos Aires, C1122AAJ, Argentina
| | - Rocío Castilla
- Instituto Alberto C Taquini de Investigaciones en Medicina Traslacional (IATIMET), CONICET, Universidad de Buenos Aires, Marcelo T. de Alvear 2270, Ciudad Autónoma de Buenos Aires, C1122AAJ, Argentina.
| |
Collapse
|
2
|
Peng Y, Tao Y, Liu L, Zhang J, Wei B. Crosstalk among Reactive Oxygen Species, Autophagy and Metabolism in Myocardial Ischemia and Reperfusion Stages. Aging Dis 2024; 15:1075-1107. [PMID: 37728583 PMCID: PMC11081167 DOI: 10.14336/ad.2023.0823-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Accepted: 08/23/2023] [Indexed: 09/21/2023] Open
Abstract
Myocardial ischemia is the most common cardiovascular disease. Reperfusion, an important myocardial ischemia tool, causes unexpected and irreversible damage to cardiomyocytes, resulting in myocardial ischemia/reperfusion (MI/R) injury. Upon stress, especially oxidative stress induced by reactive oxygen species (ROS), autophagy, which degrades the intracellular energy storage to produce metabolites that are recycled into metabolic pathways to buffer metabolic stress, is initiated during myocardial ischemia and MI/R injury. Excellent cardioprotective effects of autophagy regulators against MI and MI/R have been reported. Reversing disordered cardiac metabolism induced by ROS also exhibits cardioprotective action in patients with myocardial ischemia. Herein, we review current knowledge on the crosstalk between ROS, cardiac autophagy, and metabolism in myocardial ischemia and MI/R. Finally, we discuss the possible regulators of autophagy and metabolism that can be exploited to harness the therapeutic potential of cardiac metabolism and autophagy in the diagnosis and treatment of myocardial ischemia and MI/R.
Collapse
Affiliation(s)
- Yajie Peng
- Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
| | - Yachuan Tao
- Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
- Department of Pharmacology, School of Pharmaceutical Sciences, Fudan University, Shanghai, China
| | - Lingxu Liu
- Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
| | - Ji Zhang
- The First Affiliated Hospital of Zhengzhou University, Department of Pharmacy, Zhengzhou, Henan, China.
| | - Bo Wei
- Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
| |
Collapse
|
3
|
Tan R, Guo H, Yang Z, Yang H, Li Q, Zhu Q, Du Q. Efficacy and safety of levosimendan in patients with sepsis: a systematic review and network meta-analysis. Front Pharmacol 2024; 15:1358735. [PMID: 38523635 PMCID: PMC10957638 DOI: 10.3389/fphar.2024.1358735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Accepted: 02/21/2024] [Indexed: 03/26/2024] Open
Abstract
Objective: We conducted a systematic review to assess the advantages and disadvantages of levosimendan in patients with sepsis compared with placebo, milrinone, and dobutamine and to explore the clinical efficacy of different concentrations of levosimendan. Methods: PubMed, Web of Science, Cochrane Library, Embase, CNKI, Wanfang data, VIP, and CBM databases were searched using such keywords as simendan, levosimendan, and sepsis. The search time was from the establishment of the database to July 2023. Two researchers were responsible for literature screening and data collection respectively. After the risk of bias in the included studies was evaluated, network meta-analysis was performed using R software gemtc and rjags package. Results: Thirty-two randomized controlled trials (RCTs) were included in the network meta-analysis. Meta-analysis results showed that while levosimendan significantly improved CI levels at either 0.1 µg/kg/min (mean difference [MD] [95%CrI] = 0.41 [-0.43, 1.4]) or 0.2 µg/kg/min (MD [95%CrI] =0.54 [0.12, 0.99]). Levosimendan, at either 0.075 µg/kg/min (MD [95% CrI] =0.033 [-0.75, 0.82]) or 0.2 µg/kg/min (MD [95% CrI] = -0.014 [-0.26, 0.23]), had no significant advantage in improving Lac levels. Levosimendan, at either 0.1 µg/kg/min (RR [95% CrI] = 0.99 [0.73, 1.3]) or 0.2 µg/kg/min (RR [95% CrI] = 1.0 [0.88, 1.2]), did not have a significant advantage in reducing mortality. Conclusion: The existing evidence suggests that levosimendan can significantly improve CI and lactate levels in patients with sepsis, and levosimendan at 0.1 µg/kg/min might be the optimal dose. Unfortunately, all interventions in this study failed to reduce the 28-day mortality. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023441220.
Collapse
Affiliation(s)
- Ruimin Tan
- School of Clinical Medical, North China University of Science and Technology, Tangshan, Hebei, China
- Critical Care Department, Hebei General Hospital, Shijiazhuang, Hebei, China
| | - He Guo
- Critical Care Department, Hebei General Hospital, Shijiazhuang, Hebei, China
- School of Graduate, Hebei Medical University, Shijiazhuang, Hebei, China
| | - Zinan Yang
- Critical Care Department, Hebei General Hospital, Shijiazhuang, Hebei, China
- School of Graduate, Hebei Medical University, Shijiazhuang, Hebei, China
| | - Huihui Yang
- School of Clinical Medical, North China University of Science and Technology, Tangshan, Hebei, China
- Critical Care Department, Hebei General Hospital, Shijiazhuang, Hebei, China
| | - Qinghao Li
- Critical Care Department, Hebei General Hospital, Shijiazhuang, Hebei, China
- School of Graduate, Hebei Medical University, Shijiazhuang, Hebei, China
| | - Qiong Zhu
- Department of Orthopaedics, The People’s Hospital of Shizhu, Chongqing, China
| | - Quansheng Du
- Critical Care Department, Hebei General Hospital, Shijiazhuang, Hebei, China
| |
Collapse
|
4
|
Xie Y, Xing Z, Wei J, Sun X, Zhao B, Chen Y, Geng Y, Jia Z, Zou H. Levosimendan Postconditioning Attenuates Cardiomyocyte Apoptosis after Myocardial Infarction. JOURNAL OF HEALTHCARE ENGINEERING 2022; 2022:2988756. [PMID: 35132355 PMCID: PMC8817859 DOI: 10.1155/2022/2988756] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Accepted: 01/08/2022] [Indexed: 01/08/2023]
Abstract
BACKGROUND Levosimendan preconditioning has been shown to attenuate myocardial apoptosis in animal models. However, protective effects of levosimendan postconditioning against myocardial apoptosis following myocardial infarction (MI) have not been evaluated. Therefore, we investigated the effects of levosimendan postconditioning on myocardial apoptosis in MI rat models. METHODS In an anoxia/reoxygenation (A/R) model, H9c2 cells were pretreated with or without levosimendan postconditioning after which their apoptosis rates were assessed by flow cytometry, RT-qPCR, and western blot analyses. Then, postconditioning was performed with or without levosimendan in MI rat models. Myocardiocyte apoptosis was evaluated by echocardiography, TTC staining, TUNEL staining, immunohistochemical staining, RT-qPCR, and western blot analysis. RESULTS Levosimendan postconditioning inhibited H9c2 cell apoptosis in A/R models by elevating Bcl-2 while suppressing Caspase-3 and Bax at both mRNA and protein levels. Moreover, it improved cardiac functions and reduced the left ventricle infarction area in MI rat models. Compared to the MI control group, cardiomyocyte apoptosis rates in the levosimendan postconditioning group were low. The reduced cardiomyocyte apoptosis rates were associated with downregulation of Bax and Caspase-3 as well as with upregulation of Bcl-2 at mRNA and protein levels. CONCLUSIONS Levosimendan postconditioning of MI rat models protected against cardiomyocyte apoptosis, implying that it is a potential strategy for preventing cardiomyocyte apoptosis in the treatment of cardiac dysfunction following MI.
Collapse
Affiliation(s)
- Ying Xie
- Department of Cardiovascular Surgery, Yan'an Hospital Affiliated to Kunming Medical University, No. 245,Renmin East Road, Kunming, Yunnan Province 650051, China
| | - Zhengjiang Xing
- Department of Cardiovascular Surgery, Yan'an Hospital Affiliated to Kunming Medical University, No. 245,Renmin East Road, Kunming, Yunnan Province 650051, China
| | - Jie Wei
- Department of Cardiovascular Surgery, Yan'an Hospital Affiliated to Kunming Medical University, No. 245,Renmin East Road, Kunming, Yunnan Province 650051, China
| | - Xiaolin Sun
- Department of Cardiovascular Surgery, Yan'an Hospital Affiliated to Kunming Medical University, No. 245,Renmin East Road, Kunming, Yunnan Province 650051, China
| | - Bin Zhao
- Department of Cardiovascular Surgery, Yan'an Hospital Affiliated to Kunming Medical University, No. 245,Renmin East Road, Kunming, Yunnan Province 650051, China
| | - Yan Chen
- Department of Cardiovascular Surgery, Yan'an Hospital Affiliated to Kunming Medical University, No. 245,Renmin East Road, Kunming, Yunnan Province 650051, China
| | - Yue Geng
- Department of Cardiovascular Surgery, Yan'an Hospital Affiliated to Kunming Medical University, No. 245,Renmin East Road, Kunming, Yunnan Province 650051, China
| | - Zheng Jia
- Department of Cardiovascular Surgery, Yan'an Hospital Affiliated to Kunming Medical University, No. 245,Renmin East Road, Kunming, Yunnan Province 650051, China
| | - Honglin Zou
- Department of Cardiovascular Surgery, Yan'an Hospital Affiliated to Kunming Medical University, No. 245,Renmin East Road, Kunming, Yunnan Province 650051, China
| |
Collapse
|